Patient characteristics
| RAS | BOS | Donor | p-value | |
| Patients n | 8 | 8 | 8 | |
| Sex male/female n | 6/2 | 4/4 | 7/1 | 0.22 |
| Height cm | 171 (165–185) | 169 (162–174) | 177 (173–180) | 0.10 |
| Weight kg | 61 (55–68) | 52 (47–60)** | 80 (73–83) | 0.0025 |
| Age years | 39 (30–54) | 45 (34–57) | 55 (47–63) | 0.13 |
| Time between first and second Tx years | 5.7 (4.7–8.6) | 5.0 (3.8–7.7) | NA | 0.33 |
| ILD/CF/COPD/PH/other n | 1/2/2/1/2 | 3/2/0/0/3 | NA | |
| Time between diagnosis and reTx years | 1.5 (0.6–3.5) | 2.0 (0.9–2.6) | ||
| Donor age years | 43 (28–54) | 37 (23–44) | 0.38 | |
| Pulmonary function | ||||
| FVC % pred | 32 (23–36) | 47 (38–58) | NA | 0.0047 |
| FVC L | 1.4 (1.1–1.7) | 1.5 (1.4–2.2) | NA | 0.19 |
| FEV1/FVC | 61 (51–81) | 32 (28–41) | NA | 0.0002 |
| TLC % pred | 72 (50–84) | 101 (92–122) | NA | 0.0022 |
| DLCO % pred | 72 (50–84) | 43 (30–55) | NA | 0.029 |
| Radiology | ||||
| Time between CT and reTx days | 60 (46–88) | 22 (10–101) | NA | 0.23 |
| Expiratory CT | ||||
| Airtrapping % | 64 (14–89) | 78 (70–94) | NA | 0.69 |
| Inspiratory CT | ||||
| Bronchus dilatation % | 36 (14–61) | 53 (11–75) | NA | 0.80 |
| Centrilobular nodules % | 0 (0–0) | 0 (0–0) | NA | 0.96 |
| Airway wall thickening % | 22 (11–33) | 50 (39–69) | NA | 0.028 |
| Consolidation % | 17 (3–36) | 0 (0–0) | NA | 0.021 |
| Ground glass % | 17 (6–28) | 6 (0–17) | NA | 0.33 |
| Pleural thickening % | 64 (36–89) | 0 (0–11) | NA | 0.0003 |
| Reticular pattern % | 36 (17–61) | 0 (0–6) | NA | 0.0019 |
| Volume loss % | 36 (25–61) | 0 (0–11) | NA | 0.0006 |
Data are presented as median (interquartile range), unless otherwise stated. Transplants were performed at The University Hospital Gasthuisberg, Leuven, Belgium (n=14) or the Erasmus University Hospital, Brussels, Belgium (n=2). Donor lungs were obtained either at the University Hospital Gasthuisberg (n=5) or the University of Pennsylvania, Philadelphia, PA, USA, through the Gift of Life organisation (n=3). Donor lungs were not used because of extrapulmonary complications or not finding a suitable receptor in due time. The preoperative diagnoses included interstitial lung disease (ILD), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH), and those referred to as other include lymphangiomyelomatosis, Williams Campbell syndrome and histiocytosis X in bronchiolitis obliterans syndrome (BOS) and sarcoidosis and therapy resistant asthma in restrictive allograft syndrome (RAS). Pulmonary function included forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), total lung capacity (TLC) and diffusing capacity of the lung for carbon monoxide (DLCO). Tx: transplantation; reTx: retransplantation; CT: computed tomography; NA: not available. Displayed p-value for sex, height, weight and age is comparing BOS, RAS and control. All other p-values are comparing BOS versus RAS. **: p<0.01 versus donor. Bold p-values indicate significance.